Approval · Notice of Compliance 28712 · 2022
RESTASIS: Notice of Compliance 28712
Issued August 8, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28712
- Date
- August 8, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Merger/Buy-out
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RESTASIS | 02355655 | Marketed |
Medicinal ingredients
- CYCLOSPORINE 0.05 PER